Vizient Signs Innovative Technology Contract with Body Vision Medical
Body Vision’s AI-powered LungVision image system earned a place in Vizient’s innovative technology program.
Stock.adobe.com
Vizient signed an innovative technology contract with Body Vision Medical for its AI-powered LungVision image guidance system.1 Hospital experts on Vizient’s customer-led council recommended the system based on its potential to improve healthcare.
LungVision is designed to work with C-arm fluoroscopes to produce real-time images that doctors can use to identify and locate lung nodules, which is helpful in diagnosing and treating lung diseases such as lung cancer. Vizient’s innovative technology program will provide Body Vision Medical with contracting and marketing opportunities, along with visibility on Vizient’s online forum.
In a press release, Body Vision Medical’s vice president of sales and market development Jon Ulvestad said, “We are honored by Vizient's recognition of LungVision® as an innovative technology. LungVision's combination of real-time imaging, augmented fluoroscopy, and image-guided navigation is functionally unique in the navigational bronchoscopy space. The fact that these capabilities are found in a system that has been proven to provide superior clinical outcomes, helps reduce radiation exposure, is compatible with any existing bronchoscopy setup, and is cost-effective enough to be a viable option for medical institutions of all types is truly game-changing. Vizient's contract award makes it easier for its customers to access this innovative technology and improve their ability to definitively diagnose lung patients."
In the same press release, Kelly Flaharty, senior director of contract services for Vizient, said, “A product receives this type of contract when it demonstrates a unique quality that differentiates it from other products on the market. Our customer-led council determined that Body Vision Medical's LungVision met this standard and recognizes its potential to improve quality outcomes."
Body Vision Medical also recently announced that Matt Baker would serve as its new CEO. Baker, who previously served as the company’s chief operating officer, is replacing David Webster.2
In a press release issued at the time, Body Vision Medical’s chairman of the board Yuval Bar-Gil said, “We extend our heartfelt gratitude to David Webster for his exceptional leadership and unwavering dedication during his tenure as CEO. David's visionary guidance has put the company in a strong financial and commercial position and we are confident in Matt's ability to continue the company's growth and excellence in all aspects during this transitional period and beyond."
In March, Body Vision also announced that its LungVision system had successfully been validated with FUJIFILM Healthcare America Corporations line of C-arms.3
In a press release, Webster (who was serving as CEO of Body Vision at the time), said, “This validation further demonstrates the power of an AI-driven imaging platform like LungVision™ that enables physicians to agnostically leverage our image-guided navigation and real-time imaging with the bronchoscopy platform and C-arm of their choice. Fujifilm's C-arms demonstrate very innovative and competitive thinking and pairing them with LungVision™ helps to create a complete image-guided navigational bronchoscopy solution for targeting the most challenging lesions."
In the same press release, FUJIFILM’s director of strategic marketing for diagnostic imaging Rob Fabrizio said, “Fujifilm is committed to delivering innovative, best-of-breed solutions focused on enhancing patient experience while streamlining the procedural workflow for healthcare providers. We're elated to see the successful validation of our C-arm platforms with Body Vision's leading LungVision™ system to synergistically provide the visualization needed by bronchoscopists during navigation bronchoscopy.”
Sources
Body Vision Medical Receives Innovative Technology Contract from Vizient for LungVision. Body Vision Medical. July 9, 2024. https://www.prnewswire.com/news-releases/body-vision-medical-receives-innovative-technology-contract-from-vizient-for-lungvision-302191339.html
Body Vision Medical Announces Departure of David Webster as CEO and Appoints Matt Baker as Successor. Body Vision Medical. July 2, 2024. Accessed July 9, 2024. https://www.prnewswire.com/news-releases/body-vision-medical-announces-departure-of-david-webster-as-ceo-and-appoints-matt-baker-as-successor-302187445.html
Body Vision Medical Announces Successful Validation of LungVision™ System with Fujifilm's Range of Surgical C-arms. Body Vision Medical. March 5, 2024. Accessed July 9, 2024. https://www.prnewswire.com/news-releases/body-vision-medical-announces-successful-validation-of-lungvision-system-with-fujifilms-range-of-surgical-c-arms-302079954.html
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
